Navigation Links
Crucial Directives Must be Revised to Protect Patients' Interests and Improve Access to Treatment
Date:9/1/2011

BRUSSELS, September 1, 2011 /PRNewswire/ --

The current revision of two European Directives that are crucial to successful research into blood-related diseases must ensure the safety of patients and enhance their access to vitally-important treatment.

This was a key message of a two-day conference, "Haematology and the next European decade", hosted by the European Parliament and attended by doctors, researchers, parliamentarians, patients' organisations and Commission officials.

The revision of the Clinical Trials Directive, which provides the regulatory framework for the testing of new drugs on humans, has reached its final stages before a draft law is proposed by the European Commission within the next few months, but some politically-sensitive issues still remain.

There is a clear consensus among all stakeholders that the existing processes are overly bureaucratic, costly and time-consuming. "If we want to keep modern scientific research in Europe, we need to modernise our Directive", said Philippe Juvin MEP, the European Parliament's rapporteur on the revision.

However, haematological researchers and patients' organisations insist that seeking to reduce costs and simplify the rules in order to encourage more clinical testing in Europe must not compromise patient safety.

Also, the changes must aim to reverse the economic pressure on independent academic research - "squeezing academic research into a commercial strait-jacket" - and so facilitate a rich source of new treatments for blood-related diseases, especially rare forms of cancer.

As part of its aim to highlight the positive impact of haematology research across a range of medical conditions, the conference - organised jointly by the European Cancer Patient Coalition and the European Hematology Association, the haematologists' organisation - also discussed today the ongoing revision of the 2005 Directive relating to professional qualifications.

Both
'/>"/>

SOURCE European Hematology Association
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Researchers at the University of Georgia Discover Protein is Crucial to Reproduction of Parasites Involved in Disease
2. Novel use of MEMS microphones to map noise pollution and meet EU directives
3. Talecris Biotherapeutics Announces Revised Record Date and Meeting Date for Special Meeting of Shareholders
4. Revised: Sinovac Provides Update on Clinical Trial for H1N1 Vaccine Trials
5. Kendle to Host Conference Call to Discuss Revised 2009 Outlook
6. Cardium Reports on Third Quarter 2008 Financial Results and Revised Business Strategies for Operating Units
7. Stallergenes: Sales at end September 2008: + 17% - 2008 Sales Guidance Revised Upwards: + 14%
8. Palatin Technologies, Inc. Revised Call-In Number for Teleconference and Webcast to be held on September 30, 2008
9. Informed Medical Communications Highlights Opportunity in Revised PhRMA Code
10. Trudeau Institute announces a discovery in how FluMist elicits protection
11. PPTA Praises Legislation That Protects the Treatment of Rare Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... 2014 Continental Clinical Solutions, LLC ... clinical trials at its mid-Atlantic late-phase research facility, ... created with the idea of closing patient disparities ... in medical advances," said Continental's CEO, Saleh ... the immortal cell line of Henrietta Lacks, dubious ...
(Date:11/24/2014)... Md. , Nov. 24, 2014  Spherix ... development company committed to the fostering and monetization ... Spherix v. VTech Telecommunications Ltd.,  Case No. 3:13-cv-03494-M ... Case No. 3:13-cv-03496-M, both in the United States ... Texas . On ...
(Date:11/22/2014)... November 21, 2014 Two new educational webinars ... comes next for ALS research and how the pharmaceutical industry ... the Ice Bucket Challenge: Where Does the ALS Money Go? ... 2 December 2014, Time: 1:30pm ET, Register to ... speaker Dr. Merit Cudkowicz, Julianne Dorn Professor of Neurology at ...
(Date:11/22/2014)... 21, 2014 CannLabs, Inc. ... analytics and scientific testing methodologies relating to cannabis, today ... $750,000 line of credit from an existing stockholder of ... have secured this commitment from one of our existing ... CannLabs. “This capital will help accelerate our planned expansions ...
Breaking Biology Technology:At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 2At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 3Markman Hearing Held as Scheduled in VTech and Uniden Cases 2DrugDev Webinars in December to Explore What Comes Next for ALS Research and How We Can Make Life Easier for Clinical Sites 2CannLabs Secures $750,000 Line Of Credit 2
... (GFP) in their retina cells or other tissues can ... real time computer record of movement and gene expression. ... BMC Biotechnology , will allow detailed analyses of ... Tower led a team of researchers from the University ...
... Washington Life Sciences Discovery,Fund (LSDF) has awarded nearly $4.7 ... Alliance (WAVA) and to support initial research into,three new ... the,grant is funded by Washington,s$350 million tobacco-lawsuit-settlement bonus,and provides ... , WAVA core ...
... Office has,issued Nutraceutix, Inc. a patent for BIO-tract. It ... the technology has been awarded based,on BIO-tract,s ability to ... their way to optimal release sites in the,intestinal tract. ... Nutraceutix comments: "Many years ago,we recognized the need for ...
Cached Biology Technology:Life Sciences Discovery Fund Awards $4.7 Million to Support New Vaccine Program 2Life Sciences Discovery Fund Awards $4.7 Million to Support New Vaccine Program 3Life Sciences Discovery Fund Awards $4.7 Million to Support New Vaccine Program 4Probiotic Delivery Technology Awarded Third International Patent 2
(Date:11/18/2014)... -- The Parenteral Drug Association (PDA) today confirmed that seven ... at least seven more will participate in the upcoming 2014 ... in Washington D.C. , Dec. 2-4. ... from the regulatory agencies in the United States ... effort to help advance the use of metrics in the ...
(Date:11/12/2014)... PALM BEACH GARDENS, Fla. , Nov. 12, 2014 ... management solutions, announced today that its U.are.U ® ... upscale retail bakery chain in Central Mexico ... solution in June 2014 to eliminate payroll issues caused ... Prior to installing the U.are.U fingerprint readers, Montparnasse ...
(Date:11/7/2014)... Dr. Debra Auguste, associate professor, biomedical engineering, in ... College of New York, have identified a molecule ... of the most aggressive forms of breast cancer. ... high mortality rate owing to aggressive proliferation and ... However, Professor Auguste,s team, discovered the overexpression of ...
Breaking Biology News(10 mins):FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2
... NEW YORK , Aug. 16, 2013   EyeLock Inc. , a ... of Roger An as Vice President of Global ... for research, analysis and strategic initiatives to further the embedded ... a heavy focus on Asia .   ...
... 2013) Primary results from a new clinical ... treated with the monoclonal antibody teplizumab (MacroGenics, Inc.) ... islet cell function, compared to controls. Further analyses ... that demonstrated especially robust responses ("responders"), suggesting that ...
... body is a complicated system of blood vessels, nerves, organs, ... When all are working together, it,s a symphony of form ... Biologist Rejji Kuruvilla and her fellow researchers uncovered what happens ... along with graduate students Philip Borden and Jessica Houtz, both ...
Cached Biology News:EyeLock Appoints Roger An Vice President of Global Market Development 2EyeLock Appoints Roger An Vice President of Global Market Development 3ITN type 1 diabetes study identifies subset of patients with strong response to therapy 2ITN type 1 diabetes study identifies subset of patients with strong response to therapy 3Sympathetic neurons 'cross talk' with pancreas cells during early development 2Sympathetic neurons 'cross talk' with pancreas cells during early development 3